|
|
Vaccine Detail
|
4-peptide melanoma vaccine |
| Vaccine Information |
- Vaccine Name: 4-peptide melanoma vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: 4 melanoma peptides (NCT00938223; NCT00515528; NCIT_C91722)
- MAGEA3
gene engineering:
- Type: Recombinant protein preparation
- Description: A peptide from MAGE-3 was used for the development of this cancer vaccine .
- Detailed Gene Information: Click Here.
- Immunization Route: intradermal and subcutaneous injections
- Description: 4-peptide melanoma vaccine may stimulate an immune response against 4 different melanoma associated antigens. This may lead to a reduction in tumor cell proliferation of cancer cells expressing these antigens. (NCIT_C91722) The vaccine may contain 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a helper tetanus peptide. (NCT00938223) The peptides may include Melan-A, gp100, MAGE-3, and NA17. The vaccine can be used in combination Ontak, which may produce an immune response in patients with metastatic melanoma, and the Ontak may improve these immune responses and lead to tumor shrinkage. (NCT00515528)
|
| Host Response |
|
|
| References |
NCIT_C91722: 4-Peptide Melanoma Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91722]
NCT00515528: Vaccination Plus Ontak in Patients With Metastatic Melanoma [https://clinicaltrials.gov/study/NCT00515528]
NCT00938223: Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma (MEL39) [https://clinicaltrials.gov/study/NCT00938223]
|
|
